CoChat

A versatile drug delivery system targeting senescent cells

Open access

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Senescent cells accumulate in multiple aging‐associated diseases, and eliminating these cells has recently emerged as a promising therapeutic approach. Here, we take advantage of the high lysosomal β‐galactosidase activity of senescent cells to design a drug delivery system based on the encapsulation of drugs with galacto‐oligosaccharides. We show that gal‐encapsulated fluorophores are preferentially released within senescent cells in mice. In a model of chemotherapy‐induced senescence, gal‐encapsulated cytotoxic drugs target senescent tumor cells and improve tumor xenograft regression in combination with palbociclib. Moreover, in a model of pulmonary fibrosis in mice, gal‐encapsulated cytotoxics target senescent cells, reducing collagen deposition and restoring pulmonary function. Finally, gal‐encapsulation reduces the toxic side effects of the cytotoxic drugs. Drug delivery into senescent cells opens new diagnostic and therapeutic applications for senescence‐associated disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201809355

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Release of gal‐encapsulated fluorophores in xenografts AGalNP beads are based on a mesoporous silica scaffold (MCM‐41) that can be loaded with different cargoes encapsulated by a coat of 6‐mer β(1,4)‐galacto‐oligosaccharides. Cellular uptake of the GalNP beads occurs via endocytosis and, after fusion with lysosomal vesicles, the beads are released by exocytosis. The high lysosomal β‐galactosidase activity of senescent cells allows a preferential release of the cargo by a β‐galactosidase‐mediated hydrolysis of the cap.BSK‐MEL‐103 melanoma cells were treated with palbociclib (1 μM) for 1 week, and senescence induction was assessed by SAβgal staining. Next, cultures were exposed to GalNP(rho) (50 μg/ml, for 16 h). Pictures show representative images illustrating rhodamine release by confocal microscopy. Cells were co‐stained with Calcein, and nuclei were stained with Hoechst. Graphs to the right show the rhodamine intensity relative to cell surface in senescent cells and non‐senescent (control) cells. Each assay was repeated at least three times with similar results. Scale bar: 50 μm.CSubcutaneous tumor xenografts of SK‐MEL‐103 melanoma cells in athymic female nude mice. Upon tumor formation, mice were treated daily with palbociclib (oral gavage, 100 mg/kg) during 7 days. The left panel picture shows representative whole tissue portions of tumors after SAβGal staining. The right panel shows sections of control and palbociclib‐treated tumors processed for SAβGal staining, and Ki67 and phosphorylated Rb (p‐Rb) immunohistochemistry. This experiment has been repeated at least two times with similar results. Scale bar: 50 μm.DMice bearing SK‐MEL‐103 xenografts, control or treated with palbociclib for 7 days, as in (C), were tail vein injected with 200 μl of a solution containing GalNP(rho) (4 mg/ml). At 6 h post‐injection, mice were sacrificed, tumors were collected, and fluorescence was analyzed by an IVIS spectrum imaging system. The graph indicates the average difference in tumor radiance between GalNP‐injected control and palbociclib‐treated groups. The inset shows the absolute values of radiance (p/s/cm2/sr × 106) for each group. The corresponding differences are highlighted in black or red. Values are expressed as mean ± SD, and statistical significance was assessed by the two‐tailed Student's t‐test.
Figure 1 Release of gal‐encapsulated fluorophores in xenografts AGalNP beads are based on a mesoporous silica scaffold (MCM‐41) that can be loaded with different cargoes encapsulated by a coat of 6‐mer β(1,4)‐galacto‐oligosaccharides. Cellular uptake of the GalNP beads occurs via endocytosis and, after fusion with lysosomal vesicles, the beads are released by exocytosis. The high lysosomal β‐galactosidase activity of senescent cells allows a preferential release of the cargo by a β‐galactosidase‐mediated hydrolysis of the cap.BSK‐MEL‐103 melanoma cells were treated with palbociclib (1 μM) for 1 week, and senescence induction was assessed by SAβgal staining. Next, cultures were exposed to GalNP(rho) (50 μg/ml, for 16 h). Pictures show representative images illustrating rhodamine release by confocal microscopy. Cells were co‐stained with Calcein, and nuclei were stained with Hoechst. Graphs to the right show the rhodamine intensity relative to cell surface in senescent cells and non‐senescent (control) cells. Each assay was repeated at least three times with similar results. Scale bar: 50 μm.CSubcutaneous tumor xenografts of SK‐MEL‐103 melanoma cells in athymic female nude mice. Upon tumor formation, mice were treated daily with palbociclib (oral gavage, 100 mg/kg) during 7 days. The left panel picture shows representative whole tissue portions of tumors after SAβGal staining. The right panel shows sections of control and palbociclib‐treated tumors processed for SAβGal staining, and Ki67 and phosphorylated Rb (p‐Rb) immunohistochemistry. This experiment has been repeated at least two times with similar results. Scale bar: 50 μm.DMice bearing SK‐MEL‐103 xenografts, control or treated with palbociclib for 7 days, as in (C), were tail vein injected with 200 μl of a solution containing GalNP(rho) (4 mg/ml). At 6 h post‐injection, mice were sacrificed, tumors were collected, and fluorescence was analyzed by an IVIS spectrum imaging system. The graph indicates the average difference in tumor radiance between GalNP‐injected control and palbociclib‐treated groups. The inset shows the absolute values of radiance (p/s/cm2/sr × 106) for each group. The corresponding differences are highlighted in black or red. Values are expressed as mean ± SD, and statistical significance was assessed by the two‐tailed Student's t‐test.CC BY · PubMed Central
Figure 2 Release of gal‐encapsulated fluorophores in fibrotic lungs AC57BL/6 male mice were subjected to a single intratracheal administration bleomycin (1.5 U/kg) and analyzed 2 weeks later. Pictures at the left correspond to representative lungs after whole tissue SAβGal staining. The right panel shows sections of control and bleomycin‐treated lungs processed for SAβGal and Masson's trichrome staining to detect collagen fibers (stained in blue). Scale bar: 50 μm.BControl and bleomycin‐treated mice, as in (A), were tail vein injected with 200 μl of a solution containing GalNP(rho) (4 mg/ml). At 6 h post‐injection, mice were sacrificed and the lungs were analyzed by an IVIS spectrum imaging system, as in Fig 1D. The graph indicates the average difference in lung radiance between GalNP‐injected control and bleomycin‐treated groups. The inset shows the absolute values of radiance (p/s/cm2/sr × 106) for each group. The corresponding differences are highlighted in black or red. Values are expressed as mean ± SD, and statistical significance was assessed by the two‐tailed Student's t‐test.CControl and bleomycin‐treated mice were injected with GalNP(rho), as in (B), and lung sections were analyzed 6 h post‐injection by confocal microscopy. Pictures correspond to representative sections of control and bleomycin‐treated lungs. The graph shows % of rhodamine+ cells in fibrotic areas from bleomycin‐treated mice compared to normal lung tissue from control mice. Values are expressed as mean ± SD, and statistical significance was assessed by the two‐tailed Student's t‐test. Scale bar: 25 μm.DLung cell suspensions from control and bleomycin‐treated mice, as in (B), were analyzed by flow cytometry. The upper panels show representative dot plots of rhodamine staining in CD45−CD31− cells. The gating strategy is shown in detail in Appendix Fig S2C using as example the panel corresponding to the bleomycin‐treated lung shown here. Values in boxes correspond to the mean ± SEM, and statistical significance was assessed by the two‐tailed Student's t‐test. The lower panels show representative dot plots of rhodamine+ cells (after exclusion of CD45+ and CD31+ cells) separated in EpCAM− (fibroblasts) and EpCAM+ (epithelial cells) subpopulations. Values in boxes correspond to the mean ± SEM of these two populations. Statistical significance between the fibroblast:epithelial ratio of positivity was assessed by the two‐sided Fisher exact test (P = 0.008).EGSEA plots of published signatures of SASP and SIR (senescence‐inflammatory response) (Lasry & Ben‐Neriah, 2015) against the ranked list of differential expression between Rho+ and Rho− cells (all CD45−CD31−) from bleomycin‐treated mice (n = 3), at 2 weeks post‐bleomycin, as in (D).
Figure 2 Release of gal‐encapsulated fluorophores in fibrotic lungs AC57BL/6 male mice were subjected to a single intratracheal administration bleomycin (1.5 U/kg) and analyzed 2 weeks later. Pictures at the left correspond to representative lungs after whole tissue SAβGal staining. The right panel shows sections of control and bleomycin‐treated lungs processed for SAβGal and Masson's trichrome staining to detect collagen fibers (stained in blue). Scale bar: 50 μm.BControl and bleomycin‐treated mice, as in (A), were tail vein injected with 200 μl of a solution containing GalNP(rho) (4 mg/ml). At 6 h post‐injection, mice were sacrificed and the lungs were analyzed by an IVIS spectrum imaging system, as in Fig 1D. The graph indicates the average difference in lung radiance between GalNP‐injected control and bleomycin‐treated groups. The inset shows the absolute values of radiance (p/s/cm2/sr × 106) for each group. The corresponding differences are highlighted in black or red. Values are expressed as mean ± SD, and statistical significance was assessed by the two‐tailed Student's t‐test.CControl and bleomycin‐treated mice were injected with GalNP(rho), as in (B), and lung sections were analyzed 6 h post‐injection by confocal microscopy. Pictures correspond to representative sections of control and bleomycin‐treated lungs. The graph shows % of rhodamine+ cells in fibrotic areas from bleomycin‐treated mice compared to normal lung tissue from control mice. Values are expressed as mean ± SD, and statistical significance was assessed by the two‐tailed Student's t‐test. Scale bar: 25 μm.DLung cell suspensions from control and bleomycin‐treated mice, as in (B), were analyzed by flow cytometry. The upper panels show representative dot plots of rhodamine staining in CD45−CD31− cells. The gating strategy is shown in detail in Appendix Fig S2C using as example the panel corresponding to the bleomycin‐treated lung shown here. Values in boxes correspond to the mean ± SEM, and statistical significance was assessed by the two‐tailed Student's t‐test. The lower panels show representative dot plots of rhodamine+ cells (after exclusion of CD45+ and CD31+ cells) separated in EpCAM− (fibroblasts) and EpCAM+ (epithelial cells) subpopulations. Values in boxes correspond to the mean ± SEM of these two populations. Statistical significance between the fibroblast:epithelial ratio of positivity was assessed by the two‐sided Fisher exact test (P = 0.008).EGSEA plots of published signatures of SASP and SIR (senescence‐inflammatory response) (Lasry & Ben‐Neriah, 2015) against the ranked list of differential expression between Rho+ and Rho− cells (all CD45−CD31−) from bleomycin‐treated mice (n = 3), at 2 weeks post‐bleomycin, as in (D).CC BY · PubMed Central
Figure 3 Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts ASK‐MEL‐103 melanoma cells were treated with palbociclib (1 μM) for 1 or 14 days, and senescence induction was assessed by SAβgal staining. Next, cultures were exposed to free doxorubicin (50 μM) or GalNP(dox) (1 mg/ml, filtered) for 30 min. Pictures show representative images illustrating doxorubicin fluorescence by confocal microscopy. Scale bar: 50 μm.BSK‐MEL‐103 melanoma cells were treated with palbociclib (5 μM) for 14 days, cultures were exposed to GalNP(dox) (0.06 mg/ml, filtered), and annexin V signal was quantified over time. Representative pictures are shown in Appendix Fig S3F.CAthymic nude female mice carrying subcutaneous SK‐MEL‐103 xenografts were treated daily with palbociclib (oral gavage, 50 mg/kg) and/or GalNP(dox) (tail vein injection, 200 μl of a solution with 4 mg/ml of GalNP containing a total of 1 mg/kg of deliverable doxorubicin), alone or in combination, as indicated. For each tumor, the relative tumor volume change was calculated relative to its baseline prior to treatment. Values are expressed as mean ± SEM. Individual tumor size measurements are shown in Appendix Fig S3G.DSimilar to (B) but using GalNP(nav) (tail vein injection, 200 μl of a solution with 4 mg/ml of GalNP containing a total of 1 mg/kg of deliverable navitoclax), as indicated. Individual tumor size measurements are shown in Appendix Fig S3F.ELeft, fold change of tumor size of SK‐MEL‐103 xenografts, after the indicated daily treatments. Data for palbociclib, and for palbociclib plus GalNP(dox), correspond to the same data in panel (C), at day 17. Data for free doxorubicin (daily tail vein injection, 1 mg/kg, for 17 days) were obtained in parallel. Right, mRNA levels of cardiotoxicity markers in hearts from the same mice. Actb and Gapdh were used for input normalization. Values are relative to control mice and are expressed as mean ± SD, and statistical significance was assessed by one‐way ANOVA and Dunnett's multiple comparisons test (versus palbociclib‐alone treated group).FLeft, fold change of tumor size, as in (C), after the indicated daily treatments. Data for palbociclib, and for palbociclib plus GalNP(nav), correspond to the same data in panel (D), at day 13. Data for free navitoclax (daily oral gavage, 25 mg/kg, for 13 days) were obtained in parallel. Right, platelet levels in the blood of the same mice. Values are expressed as mean ± SEM in the case of tumor size, and as mean ± SD in the case of platelet counting, and statistical significance was assessed by one‐way ANOVA and Dunnett's multiple comparisons test (versus palbociclib‐alone treated group).
Figure 3 Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts ASK‐MEL‐103 melanoma cells were treated with palbociclib (1 μM) for 1 or 14 days, and senescence induction was assessed by SAβgal staining. Next, cultures were exposed to free doxorubicin (50 μM) or GalNP(dox) (1 mg/ml, filtered) for 30 min. Pictures show representative images illustrating doxorubicin fluorescence by confocal microscopy. Scale bar: 50 μm.BSK‐MEL‐103 melanoma cells were treated with palbociclib (5 μM) for 14 days, cultures were exposed to GalNP(dox) (0.06 mg/ml, filtered), and annexin V signal was quantified over time. Representative pictures are shown in Appendix Fig S3F.CAthymic nude female mice carrying subcutaneous SK‐MEL‐103 xenografts were treated daily with palbociclib (oral gavage, 50 mg/kg) and/or GalNP(dox) (tail vein injection, 200 μl of a solution with 4 mg/ml of GalNP containing a total of 1 mg/kg of deliverable doxorubicin), alone or in combination, as indicated. For each tumor, the relative tumor volume change was calculated relative to its baseline prior to treatment. Values are expressed as mean ± SEM. Individual tumor size measurements are shown in Appendix Fig S3G.DSimilar to (B) but using GalNP(nav) (tail vein injection, 200 μl of a solution with 4 mg/ml of GalNP containing a total of 1 mg/kg of deliverable navitoclax), as indicated. Individual tumor size measurements are shown in Appendix Fig S3F.ELeft, fold change of tumor size of SK‐MEL‐103 xenografts, after the indicated daily treatments. Data for palbociclib, and for palbociclib plus GalNP(dox), correspond to the same data in panel (C), at day 17. Data for free doxorubicin (daily tail vein injection, 1 mg/kg, for 17 days) were obtained in parallel. Right, mRNA levels of cardiotoxicity markers in hearts from the same mice. Actb and Gapdh were used for input normalization. Values are relative to control mice and are expressed as mean ± SD, and statistical significance was assessed by one‐way ANOVA and Dunnett's multiple comparisons test (versus palbociclib‐alone treated group).FLeft, fold change of tumor size, as in (C), after the indicated daily treatments. Data for palbociclib, and for palbociclib plus GalNP(nav), correspond to the same data in panel (D), at day 13. Data for free navitoclax (daily oral gavage, 25 mg/kg, for 13 days) were obtained in parallel. Right, platelet levels in the blood of the same mice. Values are expressed as mean ± SEM in the case of tumor size, and as mean ± SD in the case of platelet counting, and statistical significance was assessed by one‐way ANOVA and Dunnett's multiple comparisons test (versus palbociclib‐alone treated group).CC BY · PubMed Central
Figure 4 Therapeutic activity of gal‐encapsulated doxorubicin on pulmonary fibrosis AC57BL/6 male mice were subjected to a single intratracheal administration of bleomycin at 1.5 U/kg BW. Beginning at day 10, mice were treated daily with free doxorubicin (tail vein injection, 1 mg/kg) or with GalNP(dox) (tail vein injection, 200 μl of a solution with 4 mg/ml of GalNP containing a total of 1 mg/kg of deliverable doxorubicin), for 18 days, that is, until day 28 post‐bleomycin. Plethysmography and CT were performed at the indicated days.BPlethysmography was used to determine the ratio between lung resistance (LR) and compliance dynamics (Cdyn) in the indicated groups before and after the indicated treatments. Values are expressed as mean ± SEM, and statistical significance was assessed for each group by the two‐tailed Student's t‐test comparing the LR/Cdyn values at day 28.CRepresentative CT images of the indicated treatments at days 11 and 29 post‐bleomycin injury. Each pair of images, at days 11 and 29, correspond to the same mouse. The graph represents the ratio between the volume of fibrosis at end of treatment (day 29) and the volume of fibrosis at the beginning of treatment (day 11). Values are expressed as mean ± SEM, and statistical significance was assessed by the two‐tailed Student's t‐test.D3D isocontour‐based volume rendering of a representative lung before and after treatment with GalNP(dox). Healthy lung tissue is shown in red and fibrotic lesions are shown in gray. Ventral and lateral views are shown.ERepresentative images of Sirius red staining of lungs from mice subjected to the indicated treatments 2 days after the last CT analysis, visualized by bright field or polarized light. The graph represents the fraction of collagen per damaged area. Red represents densely packed collagen, yellow represents intermediately packed collagen, and green represents loosely packed collagen. Values are expressed as mean ± SD, and statistical significance comparing the total fraction of collagen per damaged area was assessed by the two‐tailed Student's t‐test. Scale bar: 50 μm.
Figure 4 Therapeutic activity of gal‐encapsulated doxorubicin on pulmonary fibrosis AC57BL/6 male mice were subjected to a single intratracheal administration of bleomycin at 1.5 U/kg BW. Beginning at day 10, mice were treated daily with free doxorubicin (tail vein injection, 1 mg/kg) or with GalNP(dox) (tail vein injection, 200 μl of a solution with 4 mg/ml of GalNP containing a total of 1 mg/kg of deliverable doxorubicin), for 18 days, that is, until day 28 post‐bleomycin. Plethysmography and CT were performed at the indicated days.BPlethysmography was used to determine the ratio between lung resistance (LR) and compliance dynamics (Cdyn) in the indicated groups before and after the indicated treatments. Values are expressed as mean ± SEM, and statistical significance was assessed for each group by the two‐tailed Student's t‐test comparing the LR/Cdyn values at day 28.CRepresentative CT images of the indicated treatments at days 11 and 29 post‐bleomycin injury. Each pair of images, at days 11 and 29, correspond to the same mouse. The graph represents the ratio between the volume of fibrosis at end of treatment (day 29) and the volume of fibrosis at the beginning of treatment (day 11). Values are expressed as mean ± SEM, and statistical significance was assessed by the two‐tailed Student's t‐test.D3D isocontour‐based volume rendering of a representative lung before and after treatment with GalNP(dox). Healthy lung tissue is shown in red and fibrotic lesions are shown in gray. Ventral and lateral views are shown.ERepresentative images of Sirius red staining of lungs from mice subjected to the indicated treatments 2 days after the last CT analysis, visualized by bright field or polarized light. The graph represents the fraction of collagen per damaged area. Red represents densely packed collagen, yellow represents intermediately packed collagen, and green represents loosely packed collagen. Values are expressed as mean ± SD, and statistical significance comparing the total fraction of collagen per damaged area was assessed by the two‐tailed Student's t‐test. Scale bar: 50 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 339

Metadata

Authors
Muñoz‐Espín, D., Rovira, M., Galiana, I., Giménez, C., Lozano‐Torres, B., Paez‐Ribes, M., Llanos, S., Chaib, S., Muñoz‐Martín, M., Ucero, A. C., Garaulet, G., Mulero, F., Dann, S. G., VanArsdale, T., Shields, D. J., Bernardos, A., Murguía, J. R., Martínez‐Máñez, R., & Serrano, M.
Affiliations
  • University of Cambridge (GB)
  • Spanish National Cancer Research Centre (ES)
  • Universitat de València (ES)
  • Pfizer (United States) (US)
  • Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author
  • Muñoz‐Espín, Daniel
  • Serrano, Manuel
Venue
EMBO Molecular Medicine
Published
2018-07-16
Volume
10
Issue
9
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2884253843
Cited by
339
References
64
Citations by year
2026: 33 · 2025: 48 · 2024: 52 · 2023: 45 · 2022: 48 · 2021: 28 · 2020: 52 · 2019: 31 · 2018: 2
FWCI
19.37
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • RiuNet (Universitat Politècnica de València) (submittedVersion, cc-by-nc-nd)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Secretaría de Estado de Investigación, Desarrollo e Innovación (MAT2015‐64139‐C4‐1‐R)
  • H2020 European Research Council
  • Instituto de Salud Carlos III (DTS16/00205)
  • European Regional Development Fund
  • European Social Fund
  • Institut Ruđer Bošković
  • Fundación Botín
  • Banco Santander
  • “la Caixa” Foundation
  • Cancer Research UK (C9685‐A25177, RG86786)
  • Generalitat Valenciana (PROMETEOII/2014/047)
  • Pfizer
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
senolytics, senescent cells, drug delivery systems, galactooligosaccharides, lysosomal beta-galactosidase, chemotherapy-induced senescence, palbociclib, age-related diseases
MeSH terms
Animals, beta-Galactosidase, Cell Survival, Cytotoxins, Disease Models, Animal, Drug Compounding, Fluorescent Dyes, Galactose, Lysosomes, Neoplasm Transplantation, Neoplasms, Oligosaccharides, Piperazines, Pyridines, Staining and Labeling, Drug Delivery Systems, Cellular Senescence, Mice, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A versatile drug delivery system targeting senescent cells. https://app.cochat.ai/papers/10.15252/emmm.201809355
The paper
Muñoz‐Espín, D., Rovira, M., Galiana, I., Giménez, C., Lozano‐Torres, B., Paez‐Ribes, M., Llanos, S., Chaib, S., Muñoz‐Martín, M., Ucero, A. C., Garaulet, G., Mulero, F., Dann, S. G., VanArsdale, T., Shields, D. J., Bernardos, A., Murguía, J. R., Martínez‐Máñez, R., & Serrano, M. (2018). A versatile drug delivery system targeting senescent cells. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201809355

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.